Humacyte

Humacyte is proud to announce that the FDA has granted full approval for our Acellular Tissue Engineered Vessel, a first-in-class, universally implantable, bioengineered human vessel for extremity arterial trauma. This approval is a significant milestone in regenerative medicine, offering a new treatment option for patients with severe arterial injuries. Congratulations to our incredible team and partners who made this possible! Read our Press Release Here:?https://lnkd.in/ehm-q6CX See the Prescribing Information, including Boxed Warning:?https://bit.ly/4dl5tuL #Humacyte #FDAApproval #RegenerativeMedicine #Innovation #Biotech #Firstinclass $HUMA

?? Join an upcoming Endpoints webinar this Wednesday, Mar 26th from 12:30-1 PM ET with Laura Niklason, Ph.D., M.D., Founder, President and CEO of Humacyte. She will be speaking with Ryan Cross, a senior science correspondent, about Humacyte's lab-grown blood vessels and the possibilities of building human organs and tissues. ?? She will be the last interview of the session. You don't want to miss this great discussion! See more below and at the registration page here: https://lnkd.in/g--qQNPg

On March 6th, Humacyte (#HUMA) hosted an in-person and virtual investor event featuring Dr. Michael Curi (Rutgers New Jersey Medical School), and Dr. Sammy Siada (UCSF Fresno), who joined company management to discuss the commercial plans and early market-launch success of Symvess (acellular tissue engineered vessel-tyod) for extremity arterial injury.? ? If you missed the event, you can now access the replay through this link!?https://lnkd.in/e6PY9tBd #HealthcareInnovation #Medtech #LifeSciences #Biotechnology #ExtremityArterialInjury

We hope you had a chance to visit with us or see our presentation during OPMED 2025 in San Antonio, Tx. Thank you to the Defense Strategies Institute for hosting OPMED and to all the Department of Defense (DOD) personnel who participate in the conference. We appreciate your engagement and interest in Symvess?, our first-in-class, universally implantable, bioengineered human vessel for urgent extremity arterial replacement and repair. With our recent FDA approval and full civilian and military commercial launch, we are excited about helping you and your teams understand more about this new vascular treatment option and grateful for all your questions.? These conferences are packed with great educational opportunities but often don’t leave enough time to tackle all your questions.??Please Contact Us to help you now. We look forward to continuing the conversations! ?? Contact Us Here:?https://lnkd.in/eZdSFPaK SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING at https://bit.ly/4dl5tuL See Full Important Safety Information at https://bit.ly/ATEV_ISI INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. BOXED WARNING: GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution. WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing. ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.? ATEV, Humacyte, and Symvess are trademarks of Humacyte Inc.? ? 2025 Humacyte Global Inc. All Rights Reserved. US-SYM-000210 #Humacyte #OPMED2025 #RegenerativeMedicine #Innovation #Biotech #Firstinclass $HUMA

The Humacyte team is at OPMED! Stop by booth 302 to see and learn more about Symvess?, a first-in-class, universally implantable, bioengineered human vessel for extremity vascular trauma replacement and repair. With recent FDA Approval and full civilian and military commercial launch our team is ready to meet with you! Learn more about Symvess here:?https://lnkd.in/e2jnB-eg SEE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING at https://bit.ly/4dl5tuL See Full Important Safety Information at https://bit.ly/ATEV_ISI INDICATION SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible. BOXED WARNING: GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage. DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution. WARNINGS AND PRECAUTIONS: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing. ADVERSE REACTIONS: most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection. ATEV, Symvess, and Humacyte are registered trademarks of Humacyte Global, Inc?? 2025 Humacyte Global Inc. All Rights Reserved. US-SYM-000210 #Humacyte #OPMED2025??#Innovation #Biotech #Firstinclass $HUMA

Catch the latest episode of #HealthUncensored with host Dr. Drew on Lifetime Television, airing Monday, March 17th at 7:30 AM ET/PT! This week, we’ll be highlighting: ?? VIVUS LLC – Innovators in Healthcare and treatments. ?? Humacyte – Leaders in Biotechnology. ?? 2San – Pioneers in Global Healthcare Solutions.

Trestle Biotherapeutics and Humacyte Form Research Collaboration

Humacyte is proud to announce the publication of our Budget Impact Model (BIM) for the Acellular Tissue Engineered Vessel (ATEV?)?in the Journal of Medical Economics.? For more details, please read the full press release here: https://lnkd.in/e9QhQdpN #Humacyte #HealthcareInnovation #Bioengineering #Biotech

?? Exciting news in trauma care! ?? Humacyte has received full FDA approval for its Biologics License Application (BLA) for the Acellular Tissue Engineered Vessel (ATEV). The approval is based on data from a clinical study led by Ernest "Gene" Moore, MD, trauma surgeon at Denver Health. With this approval, the ATEV is now ready for clinical use—helping save limbs and lives. It underscores how our learning health system research drives innovative solutions to improve patient outcomes and reduce amputation rates. ?? Congratulations to everyone in our system involved in this transformative work! Share this great news with your networks--and follow us to see how Denver Health research is shaping the future of trauma care. #ResearchInnovation #TraumaCare #DenverHealth #FDAApproval

Trestle Biotherapeutics is thrilled to announce a research collaboration with the incredibly talented team at Humacyte. This work will be focused on evaluating the potential for technology integration and synergies with Trestle's bioengineered human kidney tissue and Humacyte's acellular tissue engineered vessels, ATEV. This is a fantastic opportunity for our team to work with some of the true pioneers in regenerative medicine. https://lnkd.in/gYXxUrSw